“Ending the Salt Wars: Diets for the 21st Century” (Virtual Event)

David H. Ellison, M.D. 

Professor of Medicine and Physiology and Pharmacology, Director of the Oregon Clinical and Translational Research Institute, and Associate Vice President for Clinical and Translational Research

Oregon Health & Science University

David H. Ellison, M.D. is Professor of Medicine and Chemical Physiology & Biochemistry, Director of the Oregon Clinical and Translational Research Institute, and Associate Vice President for Clinical and Translational Research at Oregon Health & Science University. Prior to assuming these roles, he was Head of the Division of Nephrology and Hypertension for 13 years. He is also a Staff Physician at the Portland VA Medical Center. Dr. Ellison is board certified in Internal Medicine and Nephrology. He is the past Chair of the Subspecialty Board in Nephrology for the American Board of Internal Medicine, and past Chair of the American Heart Association’s Council on the Kidney in Cardiovascular Disease. He was Program Chair for the American Society of Nephrology’s Kidney Week in 2010, and was an elected member of its leadership council from 2018-2022.

He is an elected member of the Association of American Physicians, the American Clinical and Climatological Society and is past chair of the Kidney Molecular Biology and Genitourinary Organ Development (KMBD) study section for NIH. He also was previously a standing member of the Renal Merit Review Study Section for the Department of Veterans Affairs.

Dr. Ellison’s is a leader in understanding how salt is reabsorbed by the kidney, on the genetic basis of human hypertension, and on diuretic treatment of edema. A long-term focus of his research is the thiazide-sensitive NaCl cotransporter (NCC). His early studies helped define the distal convoluted tubule of the kidney and how mutations of NCC can lead to Gitelman syndrome. Dr. Ellison has also led efforts that have established a previously unrecognized potassium switch in the kidney, which explains beneficial effects of dietary potassium intake and defines how mutations in a novel kinase pathway cause Familial Hyperkalemic Hypertension. Finally, his group has demonstrated that the immunosuppressive drug tacrolimus causes hyperkalemia and hypertension by activating the NCC; this work has been translated to an ongoing clinical trial. All of his work melds basic and clinical approaches and has been published in top journals including Nature Medicine, the Journal of Clinical Investigation, Cell Metabolism, and the Journal of the American Society of Nephrology.

Dr. Ellison is also a practicing Nephrologist, and a dedicated teacher and mentor to medical students, residents, Nephrology fellows, and post-doctoral scientists.

Join Meeting!

Objectives

• Determine that our brains can sense deficits in water and salt and guide us to appropriate responses
• Relate how the potassium switch in the kidney links dietary potassium intake with blood pressure

Faculty Disclosure:

• Dr. Ellison has indicated the following relevant financial relationships with commercial interests:
  • Financial Relationship –  Consultant/Contractor
  • Commercial Interest / Organization – Boehringer Ingelheim Pharmaceuticals, Inc.

Planning Committee Disclosure:

Dr. Deshpande has indicated that he has no relevant financial relationships with commercial interests.
Dr. Weiss has indicated the following relevant financial relationships with commercial interests:

• Financial Relationship – Consultant/Contractor
  • Commercial Interest / Organization – Prizm LLC
    

Target Audience

Primary care physicians.

Accreditation

The University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™.   Physicians should claim only the credit commensurate with the extent of their participation in the activity.Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.”